Home/Pipeline/Nasal Influenza Vaccine

Nasal Influenza Vaccine

Influenza

Pre-clinicalActive

Key Facts

Indication

Influenza

Phase

Pre-clinical

Status

Active

Company

Abera Bioscience

About Abera Bioscience

Abera Bioscience is a clinical-stage biotech advancing a modular OMV platform for nasal vaccine delivery. Its lead program is a serotype-independent pneumococcal vaccine preparing for Phase 1, with a preclinical influenza candidate and platform potential for other infectious diseases. The company's strategy is to develop candidates to late preclinical/early clinical phases before seeking licensing partners, supported by non-dilutive funding from EU grants and organizations like CEPI. Leadership includes CEO Maria Alriksson and CSO Mats Lundgren, with foundational science from Prof. Joen Luirink.

View full company profile

Therapeutic Areas

Infectious Disease

Other Influenza Drugs

Drug	Company	Phase	Status
PanCytoVir™ (oral probenecid)	TrippBio	IND Submitted	Active
Mimotopes-004	Mimotopes	Preclinical	Active
Next-Gen / Universal Flu Vaccines	CSL Seqirus	Research / Early Clinical	Active
Oseltamivir 75 mg	MSN Laboratories	Commercial	Active
AI Programme - Influenza	Poolbeg Pharma	Discovery	Active - Target/Candidate ID
Influenza Antibodies	new/era/mabs	Research/Pre-clinical	Active
Influenza Countermeasure Program	DynPort Vaccines	Not Specified	Active
Influenza Vaccine	Medigen	Preclinical	Active
Zapnometinib (ATR-002)	Atriva Therapeutics	Phase 2	Active
EV25	Eradivir	Pre-clinical	Active
Not Specified	New Amsterdam Sciences	Pre-clinical	Active
Influenza Program	Arisan Therapeutics	Preclinical	Active